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Synovial Sarcoma (SS) is a distinct and fairly common kind of soft
tissue sarcoma, occurring most often in young adults and having a
predilection for the extremities (Enzinger and Weiss 2001). Two
histologic subtypes are recognized: the biphasic, the most typical
but less common sub-type, containing both an epithelial and a
spindle cell component; and the monophasic subtype, entirely
made up of spindle cells. A rare form of monophasic SS has been
described, containing only epithelial-like cells (Meis-Kindblom
et al, 1996). 
Cytogenetically, SS is characterized by the translocation
t(X;18)(p11.2;q11.2) in more than 95% of the cases. This translo-
cation fuses the SYT gene from chromosome 18 with one of three
closely related genes SSX1, SSX2 or SSX4, located at the X chro-
mosome. The fused genes form a chimeric protein that seems to
deregulate either the transcription or the expression of specific
target genes. The current evidence suggests that this non-random
SS translocation may be associated to the transactivation of a
cascade of genes such as c-MET (Oda et al, 2000), c-KIT
(Tamborini et al, 2001) and their ligands, and BCL-2 (Mancuso
et al, 2000), yielding two different autocrine loops, one acting on
the epithelial differentiation (c-MET), and the other working in an
apoptosis-protecting program (BCL-2, c-KIT). 
Synovial sarcoma has been traditionally regarded as a highly
malignant tumour, but its prognosis varies greatly depending on a
number of patients evaluated or clinico-pathologic features taken
into consideration. One is tumour size, that has been shown to be
an independent predictor of both distant recurrence and mortality
(Lewis et al, 2000). Another is tumour grade. Recently, two
grading systems have been proposed for SS. One is morphology-
based and depends on the presence of atypia, necrosis and mitotic
activity (Skytting et al, 1999). The second is clinico-pathologic
oriented, and takes into account patient’s age, tumour size, and
the presence of a poorly differentiated tumour component. Both
systems have been shown to split SSs into favourable and
unfavourable cases (Bergh et al, 1999). Additional biological
markers of possible prognostic significance have been recently
investigated, including Ki-67 (Inagaki et al, 2000), c-myc (Shen
et al, 2000), and the co-expression of HGF and c-MET (Oda et al,
2000). 
Two recent studies have focused on the relevance of the
different fusion gene types in affecting the outcome of disease
(Kawai et al, 1998; Nilsson et al, 1999). Both studies showed a
significant reduction of metastasis-free survival in patients
carrying the SYT-SSXI fusion type of transcript when compared
with those carrying the SYT-SSX2 fusion type. Furthermore, SYT-
SSX1 and SYT-SSX2 fusion transcripts were shown to be signifi-
cantly associated with biphasic and monophasic SSs, respectively. 
Here we report on our own series of SS patients characterized
for the presence and type of SYT-SSX fusion transcripts with the
purpose of further verifying the value of the different SYT-SSX
gene fusions as determinants of both prognosis and morphology
in SS. 
MATERIALS AND METHODS 
A total of 72 consecutive cases of SS collected between 1989 and
1999 in which frozen tissue samples were available were retrieved.
The criteria applied for the diagnosis of biphasic and monophasic
type were those reported by Enzinger and Weiss (2001) i.e., the
presence of epithelial and spindle cell components in varying
proportions in the former and a fibrosarcoma-like spindle cell
component with no demonstrable epithelial component in the
latter. Six cases were excluded from the study for the following
reasons: four patients already had metastatic disease at the time of
diagnosis, and therefore they could not be assessed for time to
occurrence of distant metastases (the primary study endpoint); one
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previously a Ewing sarcoma/pPNET of the thoracic region,
carrying the t(11;22)(q24;q12) translocation. 
The tissue samples analysed molecularly were from primary
tumours in 26 patients, from recurrences in 18, and from distant
metastases in 20 cases. 
The treatment of the patients affected by localized tumours
(primary in 26 and recurrent in 18) consisted of conservative
surgery in 41, (associated to radiation therapy whenever indi-
cated), and major disarticulation in the other 3. Systemic
chemotherapy was administered according to standard protocols,
with 31 patients treated by adjuvant or neoadjuvant therapy. 
All patients with distant metastases to lung (20 cases) had at
least one excision of the pulmonary mass(es), and 9 of them under-
went systemic chemotherapy, as well as 22 of the remaining
patients. 
Molecular analysis 
A frozen tumour fragment from each case was mechanically
disaggregated and total RNA was isolated using the RNAzoIB
extraction system (TEL-TEST, Friendswood, Texas). One µ g of
total RNA was reverse-transcribed into cDNA using oligo(dt)
primers and reverse transcriptase (Superscript, Gibco BRL,
Paisley, UK), according to the manufacturer’s recommendations.
The integrity of cDNA was tested by the amplification of the ubiq-
uitous gene β -actine (Adams et al, 1995). The detection of the
putative SYT-SSX1 and SYT-SSX2 fusion gene was carried out
with the primers SYT 5′ CAA CAG CAA GAT GCA TAC CA3′ ,
SSX1 5′ GGT GCA GTT GTT TCC CAT CG3′ and SSX2 5′ GGC
ACA GCT CTT TCC CAT CA3′ (Kawai et al, 1998). PCR condi-
tions were the following: 35 cycles of denaturation at 94˚C for 30
sec, annealing at 58˚C for 1 min, and elongation at 72˚C for 1 min.
The detection of the putative SYT-SSX4 fusion transcript was
carried out by a nested RT-PCR with the following primers: SYT
external 5′ CAA CAG CAA GAT GCA TAC CA3′ and SSX
external 5′ TGC TAT GCA CCT GAT GAC GA3′ in the first step
and SYT internal 5′ AGA CCA ACA CAG CCT GGA CCA3′ and
SSX4 5′ GGC ACA GCT GTT TCC CAT CA3′ in the second step
(Skytting et al, 1999). The thermal profile for both reactions was
identical to that mentioned for the detection of SYT-SSX1 and
SYT-SSX2, except that the annealing temperature in the first
step was 52˚C. Each reaction included cDNA from normal
mesenchymal tissue as negative control. The amplification prod-
ucts of all the PCR reactions were analysed on 2% agarose gel that
can clearly detect both the classic SYT-SSX fusion trancripts and
all the described variants (Fligman et al, 1995; Safar et al, 1998) 
All the sequence reactions were carried out using an automated
sequencing system (377 DNA Sequencer, ABI PRISM PE,
Applied Biosystem) following standard protocols. 
Statistical methods 
The association of SYT-SSX gene transcripts (SYT-SSX1 and
SYT-SSX2) with the various clinical and pathologic parameters
investigated was tested using the Pearson chi-square test, with
exact P computation (SAS Institute Inc., 1996). 
The main endpoint of the study was metastasis-free survival.
Time to distant metastasis was computed from the date of disease
diagnosis to the date of event occurrence, or the date of last
follow-up visit for patients free from distant metastases.
Metastasis-free survival curves were obtained with the Kaplan-
Meier method. The prognostic value of SSX gene transcripts on
metastasis-free survival was assessed using the Cox model, both
without and with adjustment for the following covariates: age
(< 25 versus ≥ 25 years); tumour site (head and trunk versus limbs)
tumour size (> 5 versus ≤ 5 cm); and tumour histologic subtype,
(monophasic versus biphasic). The choice of covariates and their
categorization was done before the analysis and relied on clinical
expertise and literature data. Patients for which the source of
tumour samples was a recurrent lesion represent a selected popula-
tion, in that they entered the study cohort given that they had
developed such a recurrence. Their behaviour was expected to
differ from that of patients with samples from the primary tumour.
Exploration of our data clearly showed that subjects with samples
from distant metastases differed prognostically from the remaining
ones. For this reason Cox model analyses were stratified according
to the source of the tumour sample as follows: local sample cohort,
encompassing primary tumour and/or local recurrences; and
metastatic sample cohort. The choice of covariates and their cate-
gorization was done before the analysis and relied on clinical
expertise and literature data. 
Patients who had the assessment performed on both types of
tissue (6 cases) were included in the local sample cohort. In all
such cases, the SYT-SSX gene translocation results yielded always
concordant results in the different samples. 
The covariates were entered into the Cox model by means of
0–1 indicator variables. We also tested the interaction terms
between SYT-SSX gene transcripts and the type of tumour sample
analysed or the histologic subtype. The proportional hazard
assumption implied by the model was checked using log-minus
log survival plots. Hazard ratio (HR) estimates obtained with the
Cox model were reported together with the corresponding 95%
confidence limits and associated P-value. For a given covariate, a
hazard ratio equal to one denotes a lack of prognostic effect,
whereas values above (below) one denote an increased (decreased)
risk of occurrence of the event in a particular category, compared
to the reference category. 
Analyses were carried out using SAS™ (SAS Institute Inc.,
1990). P-values reported are two-sided; a P-value below 0.05 was
considered significant, whereas a P-value between 0.10 and 0.05
was considered borderline. 
RESULTS 
Molecular analysis 
Among the 72 patients with SS (42 monophasic and 30 biphasic)
analysed for the SYT-SSX fusion genes, the SYT-SSX1 and the
SYT-SSX2 fusion types were detected in 44 (61.1%) and 26
(36.1%) of the tumours, respectively. The remaining 2 (2.8%)
cases had an SYT-SSX4 fusion transcript. 20 of the 42 (47.6%)
monophasic tumours showed a SYT-SSX1 fusion type, 20
(47.6%) a SYT-SSX2, and 2 (4.8%) a SYT-SSX4. Conversely, 24
(80%) of the 30 biphasic SSs showed a SYT-SSX1, and 6 (20%)
a SYT-SSX2 fusion type. 
By amplifying the DNA across the breakpoint region no elec-
trophoretically different bands were detected. The PCR product of
two cases were sequenced and used as positive control for SYT-
SSX1 and SYT-SSX2 fusion transcripts, respectively. The PCR
products of the two SYT-SSX4 cases were also sequenced, as well
as those of six biphasic SS showing an SYT-SSX2 fusion transcript. 
1536 A Mezzelani et al 
British Journal of Cancer (2001) 85(10), 1535–1539 © 2001 Cancer Research CampaignStatistical analysis 
The two cases carrying the SYT-SSX4 fusion transcript were
discarded. Since six cases had already been eliminated (see
Patients and Methods), the statistical analysis was performed on
64 cases, 40 SYT-SSX1 and 24 SYT-SSX2, diagnosed between
1989 and 1999, all of which had loco-regional disease at
presentation. 
The prevalence of the SYT-SSX1 transcript (Table 1) was
higher among males then females, in tumours ≤ 5 cm in size, and
in biphasic lesions. Tumour site did not appear to substantially
affect the prevalence of the SYT-SSX1 transcript, and there was no
evident trend with patient age. A borderline P was obtained for
histologic subtype (P = 0.067). 
Forty-five distant metastases were recorded. Metastasis-free
survival curves according to the type of transcript were substan-
tially overlapping in local sample cohort (Figure 1). On average,
metastasis-free survival was about 50% at 5 years. In the
metastatic sample cohort, the survival tended to be lower for SYT-
SSX1 carrying tumours (Figure 2). 
The unadjusted hazard ratio estimate for SYT-SSX (SYT-SSX1
versus SYT-SSX2) was 1.35 (95% confidence limits: 0.71–2.57;
P = 0.365). Results of the multivariable Cox regression model
are reported in Table 2. The hazard ratio estimate adjusted for age,
tumour site, tumour size and histologic sub-type was 1.61
(0.80–3.23; P = 0.183) overall. The figures obtained according to
the type of tissue sample analysed or the histologic subtype were:
1.37 (0.55–3.38) for the local sample cohort, 1.95 (0.71–5.37) for
the metastatic sample cohort (P = 0.595 for the interaction
between SYT-SSX and type of sample analysed); 1.36 (0.62–3.01)
for monophasic tumours, 2.59 (0.67–10.0) for biphasic tumours
(P = 0.406 for the interaction between SYT-SSX and histologic
subtype). Regarding the remaining covariates, a less favourable
prognosis (hazard ratio > 1) was associated with age < 25 years,
head/trunk tumour location, tumour size > 5 cm, and monophasic
histologic subtype. However, none of these differences was signif-
icant on statistical analysis. 
DISCUSSION 
The present study was undertaken to further evaluate the predic-
tive value of the two alternative forms of the SYT-SSX fusion tran-
script (SYT-SSX1 and SYT-SSX2), concerning the prognosis and
the morphology of SS. 
The statistically valuable case material consisted of 64 cases
where samples were obtained from 44 local tumours (26 primary
and 18 local recurrent tumours) and 20 metastases. The tumours
were classified as 38 monophasic and 26 biphasic and characterized
as 40 with SYT-SSX1 and 24 with SYT-SSX2. PCR amplification
and the subsequent electrophoretical analysis of the obtained prod-
ucts revealed band size compatible with the presence of the usual
SYT-SSX genes fusion types in all the cases. For this reason after
having verified the sequence of control cases we did not perform the
DNA sequencing of all the PCR products, in the light also of Nilsson
et al data which did not find uncommon rearrangements in fusion
transcripts of the same size (Nilsson et al, 1999). 
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Table 1 Prevalence of SSX1 transcripts according to main patient and
disease characteristics 
No. of cases SSX1 % P
Sex 0.118 
Female 36 19 52.8 
Male 28 21 75.0 
Age (years) 0.115 
≤ 20 12 7 58.3 
21–30 16 11 68.8 
31–40 12 4 33.3 
41–50 15 10 66.7 
> 50 9 8 88.9 
Tumour site 1.000 
Limbs 44 28 63.6 
Head/trunk 20 12 60.0 
Tumour size (cm) 0.196 
NR 14 7 50.0 
≤ 5 19 15 79.0 
> 5 31 18 58.1 
Histologic sub-type 0.067 
Monophasic 38 20 52.6 
Biphasic 26 20 76.9 
0.0





















Figure 1 Metastasis-free survival curves according to the type of transcript
in the local sample cohort 
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Figure 2 Metastasis-free survival curves according to the type of transcript
in the metastatic sample cohort According to the same authors a tumour gene profile assessed
on samples from patients enrolled at the time of primary/recurrent
tumours may differ from that performed on samples from patients
with metastatic disease (Nilsson et al, 1999). By contrast, the
translocation (X;18)(p11.2;q11.2) is a non-random genetic hall-
mark stable over the disease progression. Thus, after a preliminary
analysis performed in our series showing that cases with primary
tumour or local recurrence samples (local sample cohort) had
similar outcome in terms of metastasis-free survival, we split our
case material into local and metastatic sample cohorts. In such a
way we accounted for the heterogeneity in the tumour material
used, at variance with previous work done by Kawai et al (1998).
There was also some evidence of a possible imbalance in the
distribution of a known prognostic characteristic such as tumour
size between SYT-SSX1 and SYT-SSX2 cases (Table 1). Cox
model multivariable analysis was aimed at removing possible
confounding due to such an association. 
As estimated by hazard ratios (HR) of the multivariate Cox regres-
sion model, tumour size turned out to be the factor more strongly
associated with poor prognosis (HR = 1.89), followed by the type of
SYT-SSX fusion (HR = 1.61). When investigating the effect of the
different SYT-SSX transcripts according to the type of sample and
histologic subtype, we observed a higher HR in the group of the
metastatic sample cohort (HR 1.95) than in the local sample cohort
(HR 1.36), and in biphasic tumours (HR 1.95) than in monophasic
ones (HR 1.36). All together, the data were consistent with a clear,
though not significant, less favourable prognostic effect of the SYT-
SSX1 fusion type in metastatic sample cohort and biphasic tumours. 
As compared with previous findings our HR estimates were
clearly lower. In particular the findings observed by multivariate
analysis were 3.0 (95% confidence limits, 1.1–0.80, P = 0.003) in
the first series published (Kawai et al, 1998) and 7.4 (1.5–36.0, 
P = 0.004) in the second one (Nilsson et al, 1999). Notably, the
latter considered only patients with SYT-SSX fusion transcripts
assessed on primary tumours, whereas in the former, the fusion
transcript assessment was performed not only on primary tumour,
but also on local recurrence and metastasis. 
Regarding tumour size, our results confirm also the well-
established (Brodsky et al, 1992) and recently-reconfirmed
evidence (Lewis et al, 2000; Machen et al, 1999) of an association
between large tumour size (> 5 cm) and poor clinical outcome.
Among the remaining variables considered, the age < 25 years, the
axial tumour location and the monophasic pattern correlated,
though not significantly, with a less favourable outcome in
keeping again with the literature (Bergh et al, 1999). 
The analysis of association between fusion transcripts and
clinico-pathological variables showed, in addition to a higher
prevalence of SYT-SSX1 in males, and in tumour smaller than 5
cm in diameter, an association, with a borderline P value (P =
0.067), between such a fusion transcript and the biphasic SS
subtype. We observed in fact six (23%) biphasic SSs carrying a
sequence-verified SYT-SSX2 fusion transcript. Interestingly three
out of six belonged to children, and involved uncommon sites. It is
worth mentioning that the Fisher’s exact test performed on the
entire series of 70 cases (see Materials and Methods), yielded a
significant result (P = 0.010) (Mezzelani et al, 2000), in keeping
with recent reports (Kawai et al, 1998; Antonescu et al, 2000). 
In conclusion we reconfirm the association between the type of
SYT-SSX fusion transcript and histologic sub-type. Regarding the
clinical outcome, our data show a trend, not reaching statistical
significance, of the SYT-SSX fusion transcript as an independent
prognostic factor coherent with previous findings. However, in
consideration of the heterogeneous effects estimated for this factor
in currently available studies, we think that the prognostic effect of
SYT-SSX fusion transcript deserves further confirmation on larger
patient groups. 
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